Exact Sciences reported first-quarter revenues this week that beat market expectations, and the cancer detection company’s executives still believe they’re on track to meet expected 2024 revenue. That’s usually good news. Yet Exact shares are down nearly 11% on Thursday, dipping to $53.12 within the first few hours of trading. During after-hours trading...

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world. These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly...

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Ways & Means strikes first Yesterday, leaders of the House Ways & Means Committee passed a two-year extension of expiring Medicare telehealth...

Even with the recent awareness that clinical trials often lack the diversity that would make them representative, women and people of color remain underrepresented in studies. The work of bringing diversity to research is complex, and several experts gathered at the Milken Institute Global Conference on Wednesday to discuss potential strategies to make...

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. I love the Cytokinetics story. There’s so much at stake with aficamten, not to mention all the ups and downs from previous drug-development efforts and now the speculation about...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Congratulations on almost making it to the end of the week! For that, I have a little treat for you at the bottom of the newsletter.Read the rest…